Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature

Detalhes bibliográficos
Autor(a) principal: Vigarinho, Michele Eugênio da Silva
Data de Publicação: 2022
Outros Autores: De Domenico, Edvane Birelo Lopes, Matsubara, Maria das Graças Silva
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/2708
Resumo: Introduction: Advances onco-hematological cancer-related treatment have resulted in an increasing number of patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) with therapeutic success, which requires more attention to the quality-of-life (QoL) of survivors. Objective: To identify the QoL of onco-hematologic survivors undergoing HSCT. Method: Integrative review, from 2011 to 2021 with search in the databases LILACS, MEDLINE, IBECS, SciELO and the Cochrane Library. The SPIDER strategy was used to answer the guiding questions; and the level of evidence was classified according to the Joanna Briggs Institute. Results: Twenty-six articles were included. The most used instruments to measure QoL were Quality of Life Questionnaire – Core 30 and Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Biopsychosocial, educational and clinical variables, such as comorbidities, history, epidemiological conditions and type of conditioning did not significantly influence the QoL of onco-hematological survivors undergoing HSCT. Quality-of-life was impaired by chronic physical problems, readmissions, financial burdens, graft-versus-host disease, fatigue, psychological symptoms, recurrent infections, dysfunctions in sexual and fertile functioning, secondary neoplasms and physical symptoms such as pain and sleep disorders. Conclusion: The HSCT survivor has continuous demands for biopsychosocial care which negatively impact the QoL and require multidimensional attention.
id INCA-1_78b80488280742be42536c376849e0de
oai_identifier_str oai:rbc.inca.gov.br:article/2708
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review LiteratureCalidad de Vida de Sobrevivientes de Cáncer Oncohematológico Sometidos a Trasplante de Células Madre Hematopoyéticas: Revisión Integradora de la LiteraturaQualidade de Vida de Sobreviventes de Câncer Onco-hematológicos Submetidos ao Transplante de Células-Tronco Hematopoiéticas: Revisão Integrativa da Literaturaqualidade de vidatransplante de células-tronco hematopoéticashematologiasobreviventes de câncerneoplasiasquality of lifehematopoietic stem cell transplantationhematologycancer survivorsneoplasmscalidad de vidatrasplante de células madre hematopoyéticashematologíasupervivientes de cáncerneoplasiasIntroduction: Advances onco-hematological cancer-related treatment have resulted in an increasing number of patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) with therapeutic success, which requires more attention to the quality-of-life (QoL) of survivors. Objective: To identify the QoL of onco-hematologic survivors undergoing HSCT. Method: Integrative review, from 2011 to 2021 with search in the databases LILACS, MEDLINE, IBECS, SciELO and the Cochrane Library. The SPIDER strategy was used to answer the guiding questions; and the level of evidence was classified according to the Joanna Briggs Institute. Results: Twenty-six articles were included. The most used instruments to measure QoL were Quality of Life Questionnaire – Core 30 and Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Biopsychosocial, educational and clinical variables, such as comorbidities, history, epidemiological conditions and type of conditioning did not significantly influence the QoL of onco-hematological survivors undergoing HSCT. Quality-of-life was impaired by chronic physical problems, readmissions, financial burdens, graft-versus-host disease, fatigue, psychological symptoms, recurrent infections, dysfunctions in sexual and fertile functioning, secondary neoplasms and physical symptoms such as pain and sleep disorders. Conclusion: The HSCT survivor has continuous demands for biopsychosocial care which negatively impact the QoL and require multidimensional attention.Introducción: Los avances en el tratamiento relacionado con el cáncer oncohematológico han dado como resultado un número creciente de pacientes sometidos a trasplante de células progenitoras hematopoyéticas (TPH) con éxito terapéutico, lo que requiere una mayor atención a la calidad de vida (CV) de los sobrevivientes. Objetivo: Identificar la CV de sobrevivientes oncohematológicos sometidos a TPH. Método: Revisión integradora, entre 2011 y 2021 con búsqueda en las bases de datos LILACS, MEDLINE, IBECS, SciELO y Cochrane Library. Se utilizó la estrategia SPIDER para responder las preguntas orientadoras; y el nivel de evidencia se clasificó según el Instituto Joanna Briggs. Resultados: Se incluyeron veintiséis artículos. Los instrumentos más utilizados para medir la CV fueron Quality of Life Questionnare – Core 30 y Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Variables biopsicosociales, educativas y clínicas, como comorbilidades, antecedentes, condiciones epidemiológicas y tipo de condicionamiento no influyeron significativamente en la CV de los sobrevivientes oncohematológicos sometidos a TPH. La calidad de vida se vio afectada en presencia de: problemas físicos crónicos, reingresos, cargas financieras, enfermedad de injerto contra huésped, fatiga, síntomas psicológicos, infecciones recurrentes, disfunciones en el funcionamiento sexual y fértil, neoplasias secundarias y síntomas físicos como dolor y trastornos del sueño. Conclusión: El sobreviviente del TPH mantiene demandas de atención biopsicosocial que influyen negativamente en la CV, evidenciando la necesidad de atención multidimensional.Introdução: Os avanços no tratamento relacionado ao câncer onco-hematológico têm resultado em um crescente número de pacientes submetidos ao transplante de células tronco-hematopoiéticas (TCTH) com êxito terapêutico, o que exige maior atenção com a qualidade de vida (QV) dos sobreviventes. Objetivo: Identificar a QV dos sobreviventes onco-hematológicos submetidos ao TCTH. Método: Revisão integrativa, entre 2011 a 2021, com busca nas bases de dados LILACS, MEDLINE, IBECS, SciELO e Biblioteca Cochrane. Utilizou-se a estratégia SPIDER para responder às questões norteadoras; e o nível de evidência foi classificado segundo o Instituto Joanna Briggs. Resultados: Vinte e seis artigos foram incluídos. Os instrumentos mais utilizados para medir a QV foram o Quality of Life Questionnare – Core 30 e o Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Variáveis biopsicossociais, educacionais e clínicas, como comorbidades, antecedentes, condições epidemiológicas e tipo de condicionamento não influenciaram significativamente a QV dos sobreviventes onco-hematológico submetidos ao TCTH. A QV apresentou comprometimento na vigência de problemas físicos crônicos, reinternações, encargos financeiros, doença do enxerto contra o hospedeiro, fadiga, sintomas psicológicos, infecções recorrentes, disfunções no funcionamento sexual e fértil, neoplasias secundárias e sintomas físicos como dor e distúrbios do sono. Conclusão: O sobrevivente do TCTH mantém demandas de cuidados biopsicossociais que influenciam negativamente a QV, evidenciando a necessidade de cuidado multidimensional.INCA2022-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de literaturaapplication/pdfapplication/pdftext/htmlhttps://rbc.inca.gov.br/index.php/revista/article/view/270810.32635/2176-9745.RBC.2022v68n4.2708Revista Brasileira de Cancerologia; Vol. 68 No. 4 (2022): Oct./Nov./Dec.; e-212708Revista Brasileira de Cancerologia; Vol. 68 Núm. 4 (2022): oct./nov./dic.; e-212708Revista Brasileira de Cancerologia; v. 68 n. 4 (2022): out./nov./dez.; e-2127082176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/2708/2441https://rbc.inca.gov.br/index.php/revista/article/view/2708/3086https://rbc.inca.gov.br/index.php/revista/article/view/2708/2469Copyright (c) 2022 Revista Brasileira de Cancerologiahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessVigarinho, Michele Eugênio da SilvaDe Domenico, Edvane Birelo LopesMatsubara, Maria das Graças Silva2023-08-08T15:14:04Zoai:rbc.inca.gov.br:article/2708Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2023-08-08T15:14:04Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
Calidad de Vida de Sobrevivientes de Cáncer Oncohematológico Sometidos a Trasplante de Células Madre Hematopoyéticas: Revisión Integradora de la Literatura
Qualidade de Vida de Sobreviventes de Câncer Onco-hematológicos Submetidos ao Transplante de Células-Tronco Hematopoiéticas: Revisão Integrativa da Literatura
title Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
spellingShingle Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
Vigarinho, Michele Eugênio da Silva
qualidade de vida
transplante de células-tronco hematopoéticas
hematologia
sobreviventes de câncer
neoplasias
quality of life
hematopoietic stem cell transplantation
hematology
cancer survivors
neoplasms
calidad de vida
trasplante de células madre hematopoyéticas
hematología
supervivientes de cáncer
neoplasias
title_short Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
title_full Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
title_fullStr Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
title_full_unstemmed Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
title_sort Quality of Life of Oncohematologic Cancer Survivors Undergoing Hematopoietic Stem Cell Transplantation: Integrative Review Literature
author Vigarinho, Michele Eugênio da Silva
author_facet Vigarinho, Michele Eugênio da Silva
De Domenico, Edvane Birelo Lopes
Matsubara, Maria das Graças Silva
author_role author
author2 De Domenico, Edvane Birelo Lopes
Matsubara, Maria das Graças Silva
author2_role author
author
dc.contributor.author.fl_str_mv Vigarinho, Michele Eugênio da Silva
De Domenico, Edvane Birelo Lopes
Matsubara, Maria das Graças Silva
dc.subject.por.fl_str_mv qualidade de vida
transplante de células-tronco hematopoéticas
hematologia
sobreviventes de câncer
neoplasias
quality of life
hematopoietic stem cell transplantation
hematology
cancer survivors
neoplasms
calidad de vida
trasplante de células madre hematopoyéticas
hematología
supervivientes de cáncer
neoplasias
topic qualidade de vida
transplante de células-tronco hematopoéticas
hematologia
sobreviventes de câncer
neoplasias
quality of life
hematopoietic stem cell transplantation
hematology
cancer survivors
neoplasms
calidad de vida
trasplante de células madre hematopoyéticas
hematología
supervivientes de cáncer
neoplasias
description Introduction: Advances onco-hematological cancer-related treatment have resulted in an increasing number of patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) with therapeutic success, which requires more attention to the quality-of-life (QoL) of survivors. Objective: To identify the QoL of onco-hematologic survivors undergoing HSCT. Method: Integrative review, from 2011 to 2021 with search in the databases LILACS, MEDLINE, IBECS, SciELO and the Cochrane Library. The SPIDER strategy was used to answer the guiding questions; and the level of evidence was classified according to the Joanna Briggs Institute. Results: Twenty-six articles were included. The most used instruments to measure QoL were Quality of Life Questionnaire – Core 30 and Functional Assessment Cancer Therapy-Bone Marrow Transplantation. Biopsychosocial, educational and clinical variables, such as comorbidities, history, epidemiological conditions and type of conditioning did not significantly influence the QoL of onco-hematological survivors undergoing HSCT. Quality-of-life was impaired by chronic physical problems, readmissions, financial burdens, graft-versus-host disease, fatigue, psychological symptoms, recurrent infections, dysfunctions in sexual and fertile functioning, secondary neoplasms and physical symptoms such as pain and sleep disorders. Conclusion: The HSCT survivor has continuous demands for biopsychosocial care which negatively impact the QoL and require multidimensional attention.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Revisão de literatura
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2708
10.32635/2176-9745.RBC.2022v68n4.2708
url https://rbc.inca.gov.br/index.php/revista/article/view/2708
identifier_str_mv 10.32635/2176-9745.RBC.2022v68n4.2708
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2708/2441
https://rbc.inca.gov.br/index.php/revista/article/view/2708/3086
https://rbc.inca.gov.br/index.php/revista/article/view/2708/2469
dc.rights.driver.fl_str_mv Copyright (c) 2022 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
text/html
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 68 No. 4 (2022): Oct./Nov./Dec.; e-212708
Revista Brasileira de Cancerologia; Vol. 68 Núm. 4 (2022): oct./nov./dic.; e-212708
Revista Brasileira de Cancerologia; v. 68 n. 4 (2022): out./nov./dez.; e-212708
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042232822333440

Registros relacionados